Loading organizations...
Jumpcode Genomics, based in San Diego, California, develops CRISPRclean technology that uses the CRISPR/Cas system to remove unwanted nucleic acid sequences from NGS libraries, improving sensitivity and reducing background noise. This patented solution simplifies workflows, cuts costs, and enables the detection of novel signals in fields such as oncology, infectious disease, and basic research. The company has raised $21 million in total funding, including a February 2021 Series B co-led by Baird Capital and Arboretum Ventures, for an estimated $32 million valuation and $10 million in annual revenue. With 11-20 employees, Jumpcode Genomics is led by CEO Mike Salter and Chief Scientist Stanley Nelson, with Frank Witney on its Board of Directors. It was founded in 2016 by Keith Brown.
Jumpcode Genomics has raised $21.0M across 1 funding round.
Jumpcode Genomics has raised $21.0M in total across 1 funding round.
Jumpcode Genomics has raised $21.0M across 1 funding round. Most recently, it raised $21.0M Series B in February 2021.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Feb 19, 2021 | $21M Series B | Arboretum Ventures, Michael Liang | Lyzz Capital | Announced |
Jumpcode Genomics has raised $21.0M in total across 1 funding round.
Jumpcode Genomics's investors include Arboretum Ventures, Michael Liang, LYZZ Capital.
